NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Klingemann HG, Martinson J (2004) Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 6:15–22
Suck G, Koh MB (2010) Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors. Hematol Oncol Stem Cell Ther 3:135–142
Childs RW, Berg M (2013) Bringing natural killer cells to the clinic: ex vivo manipulation. Hematol Am Soc Hematol Educ Progr 2013:234–246
Gong JH, Maki G, Klingemann HG (1994) Characterization of a human cell line (nk-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652–658
Tam YK, Martinson JA, Doligosa K, Klingemann HG (2003) Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5:259–272
Tonn T, Becker S, Esser R, Schwabe D, Seifried E (2001) Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 10:535–544
Maki G, Klingemann HG, Martinson JA, Tam YK (2001) Factors regulating the cytotoxic activity of the human natural killer cell line, nk-92. J Hematother Stem Cell Res 10:369–383
Luetke-Eversloh M, Killig M, Romagnani C (2013) Signatures of human nk cell development and terminal differentiation. Front Immunol 4:499
Matsuo Y, Drexler HG (2003) Immunoprofiling of cell lines derived from natural killer-cell and natural killer-like t-cell leukemia-lymphoma. Leuk Res 27:935–945
Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, Bergemann TL, McQueen KL, Guethlein LA, Parham P, Miller JS (2007) A subpopulation of human peripheral blood nk cells that lacks inhibitory receptors for self-mhc is developmentally immature. Blood 110:578–586
Faure M, Long EO (2002) Kir2dl4 (cd158d), an nk cell-activating receptor with inhibitory potential. J Immunol 168:6208–6214
Pazmany L, Mandelboim O, Vales-Gomez M, Davis DM, Reyburn HT, Strominger JL (1996) Protection from natural killer cell-mediated lysis by hla-g expression on target cells. Science 274:792–795
Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T (2005) Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33:344–352
Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, Kinet JP, Long EO (1996) Recruitment of tyrosine phosphatase hcp by the killer cell inhibitor receptor. Immunity 4:77–85
Heidenreich S, ZuEulenburg C, Hildebrandt Y, Stubig T, Sierich H, Badbaran A, Eiermann TH, Binder TM, Kroger N (2012) Impact of the nk cell receptor lir-1 (ilt-2/cd85j/lilrb1) on cytotoxicity against multiple myeloma. Clin Dev immunol. 2012:652130
Suck G, Branch DR, Smyth MJ, Miller RG, Vergidis J, Fahim S, Keating A (2005) Khyg-1, a model for the study of enhanced natural killer cell cytotoxicity. Exp Hematol 33:1160–1171
Gong JH, Maki G, Klingemann HG (1994) Characterization of a human cell line (nk-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 8:652–658
Klingemann HG, Wong E, Maki G (1996) A cytotoxic nk-cell line (nk-92) for ex vivo purging of leukemia from blood. Biol Blood Marrow Transplant Biol Blood Marrow Transplant 2:68–75
Yan Y, Steinherz P, Klingemann HG, Dennig D, Childs BH, McGuirk J, O’Reilly RJ (1998) Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4:2859–2868
Lowdell MW, Theocharous P (1997) “Less is more”: the role of purging in hematopoietic stem cell transplantation. Oncologist 2:268–274
Yahng SA, Yoon JH, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Kim Y, Cho SG (2014) Influence of ex vivo purging with clinimacs cd34(+) selection on outcome after autologous stem cell transplantation in non-Hodgkin lymphoma. Br J Haematol 164:555–564
Bais S, Bartee E, Rahman MM, McFadden G, Cogle CR (2012) Oncolytic virotherapy for hematological malignancies. Adv Virol 2012:186512
Maki G, Tam YK, Berkahn L, Klingemann HG (2003) Ex vivo purging with nk-92 prior to autografting for chronic myelogenous leukemia. Bone Marrow Transplant 31:1119–1125
Maki G (2001) Ex vivo purging of stem cell autografts using cytotoxic cells. J Hematother Stem Cell Res 10:545–551
Klingemann HG (2013) Cellular therapy of cancer with natural killer cells-where do we stand? Cytotherapy 15:1185–1194
Tonn T, Seifried E (2006) Natural killer cells for the treatment of malignancies. Transfus Med Hemother 33:144–149
Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15:1563–1570
Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H (2008) Infusion of the allogeneic cell line nk-92 in patients with advanced renal cell cancer or melanoma: a phase i trial. Cytotherapy 10:625–632
Tam YK, Miyagawa B, Ho VC, Klingemann HG (1999) Immunotherapy of malignant melanoma in a scid mouse model using the highly cytotoxic natural killer cell line nk-92. J Hematother 8:281–290
Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, Gee A, Durett A, Lindblad R, Wood D, Styers D (2011) Shipping of therapeutic somatic cell products. Cytotherapy 13:201–213
Koepsell SA, Kadidlo DM, Fautsch S, McCullough J, Klingemann H, Wagner JE, Miller JS, McKenna DH Jr (2013) Successful “in-flight” activation of natural killer cells during long-distance shipping. Transfusion 53:398–403
Suck G, Branch DR, Aravena P, Mathieson M, Helke S, Keating A (2006) Constitutively polarized granules prime khyg-1 nk cells. Int Immunol 18:1347–1354
Suck G, Branch DR, Keating A (2006) Irradiated khyg-1 retains cytotoxicity: Potential for adoptive immunotherapy with a natural killer cell line. Int J Radiat Biol 82:355–361
Suck G, Tan SM, Chu S, Niam M, Vararattanavech A, Lim TJ, Koh MB (2011) Khyg-1 and nk-92 represent different subtypes of lfa-1-mediated nk cell adhesiveness. Front Biosci 3:166–178
Mallett CL, McFadden C, Chen Y, Foster PJ (2012) Migration of iron-labeled khyg-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. Cytotherapy 14:743–751
Swift BE, Williams BA, Kosaka Y, Wang XH, Medin JA, Viswanathan S, Martinez-Lopez J, Keating A (2012) Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica 97:1020–1028
Yagita M, Huang CL, Umehara H, Matsuo Y, Tabata R, Miyake M, Konaka Y, Takatsuki K (2000) A novel natural killer cell line (khyg-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation. Leukemia 14:922–930
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified t cells in chronic lymphoid leukemia. N Engl J Med 365:725–733
Wieczorek A, Uharek L (2013) Genetically modified t cells for the treatment of malignant disease. Transfus Med Hemother 40:388–402
Bhat R, Watzl C (2007) Serial killing of tumor cells by human natural killer cells–enhancement by therapeutic antibodies. PLoS ONE 2:e326
Choi PJ, Mitchison TJ (2013) Imaging burst kinetics and spatial coordination during serial killing by single natural killer cells. Proc Natl Acad Sci USA 110:6488–6493
Boissel L, Betancur M, Lu W, Wels WS, Marino T, Van Etten RA, Klingemann H (2012) Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leuk Lymphoma 53:958–965
Suck G (2006) Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol 16:412–418
Boissel L, Betancur M, Wels WS, Tuncer H, Klingemann H (2009) Transfection with mrna for cd19 specific chimeric antigen receptor restores nk cell mediated killing of cll cells. Leuk Res 33:1255–1259
Muller T, Uherek C, Maki G, Chow KU, Schimpf A, Klingemann HG, Tonn T, Wels WS (2008) Expression of a cd20-specific chimeric antigen receptor enhances cytotoxic activity of nk cells and overcomes nk-resistance of lymphoma and leukemia cells. Cancer Immunol Immunother 57:411–423
Boissel L, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H (2013) Retargeting nk-92 cells by means of cd19- and cd20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology 2:e26527
Miller JS (2013) Therapeutic applications: Natural killer cells in the clinic. Hematol Am Soc Hematol Educ Progr 2013:247–253
Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, Wels W (2002) Retargeting of natural killer-cell cytolytic activity to erbb2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100:1265–1273
Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, Settles M, Uherek C, Wels W, Schlegel J, Rummeny EJ (2005) In vivo tracking of genetically engineered, anti-her2/neu directed natural killer cells to her2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 15:4–13
Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Senekowitsch-Schmidtke R, Henning TD, Wels WS, Uherek C, Rummeny EJ, Daldrup-Link HE (2008) Tracking of [18f]fdg-labeled natural killer cells to her2/neu-positive tumors. Nucl Med Biol 35:579–588
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS (2015) Selective inhibition of tumor growth by NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor. Mol Ther 23:330–338
Tam YK, Maki G, Miyagawa B, Hennemann B, Tonn T, Klingemann HG (1999) Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy. Hum Gene Ther 10:1359–1373
Reid GS, Bharya S, Klingemann HG, Schultz KR (2002) Differential killing of pre-b acute lymphoblastic leukaemia cells by activated nk cells and the nk-92 ci cell line. Clin Exp Immunol 129:265–271